Evaluation of renoprotective efficacy & safety of pentoxifylline vs dapagliflozin as an add-on therapy to metformin, glimepiride and telmisartan in patients with diabetic nephropathy: A randomized controlled clinical study - nil

Bhagat Phool Singh Govt. Medical College For Women0 个研究点目标入组 0 人开始时间: 待定最近更新: 2023年11月13日

试验速览

暂无简介。

•1. Subjects of more than 18 years of age of either gender suffering from type T2DM who are
•taking metformin, telmisartan plus glimepiride with persistent albuminuria >30mg/24 hour
•and estimated Glomerular filtration rate (eGFR) 45 to 90 mL/min/1.73m2.
•2. Subjects with controlled blood pressure (=140/90) with medication.
•3. Subjects with HbA1c <7% with medication.

•1. Subject refusing for written informed consent.
•2. Subjects with type 1 diabetes mellitus.
•3. Subjects with history of cerebral haemorrhage.
•4. Subjects with history of any bleeding disorder.
•5. Subjects with acute myocardial infarction or severe coronary disease.
•6. Subjects with history of malignant disease, non-diabetic kidney disease.
•7. Subjects with eGFR <45mL/min/1.73m2
•or more than 90 mL/min/1.73m2.
•8. Subjects with symptoms suggestive of Urinary tract infection.
•9. Subjects who have a history of hypersensitivity to any of the study drugs or any
•contraindication to any drug involved in this study.
•10. Subjects with Baseline Serum Potassium concentration >5.5 mEq/L.
•11. Subjects which are currently on dapagliflozin, pentoxifylline or other SGLT2 inhibitors.
•12. Pregnant and breast-feeding females.
•13. Subjects with history of drug allergy to theophylline and caffeine.
•14. Subjects currently using ketorolac, warfarin, metoprolol, aspirin, clopidogrel, furosemide.

发起方

Bhagat Phool Singh Govt. Medical College For Women